eukarys Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$717K
- Investors
-
2
eukarys General Information
Description
Developer of an artificial eukaryotic expression system designed to facilitate biomanufacturing yield enhancement. The company's products utilize proprietary artificial RNA polymerase technology, mRNA-based productivity boosters, and post-transcriptional modification processing to provide protein production synthesis, biologic quality preservation, and industrial scale-up, enabling pharmaceutical and biotechnology companies to increase production efficiency and manage development costs through a unified digital environment.
Contact Information
Website
www.eukarys.comCorporate Office
- Genopole Campus, 4 rue Pierre Fontaine
- 91058 Evry
- France
Corporate Office
- Genopole Campus, 4 rue Pierre Fontaine
- 91058 Evry
- France
eukarys Timeline
eukarys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 01-Nov-2026 | $717K | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | 10-Jun-2025 | Completed | Generating Revenue |
eukarys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
eukarys Patents
eukarys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021322707-A1 | Artificial eukaryotic expression system with enhanced performances | Active | 04-Aug-2020 | ||
| AU-2021322707-B2 | Artificial eukaryotic expression system with enhanced performances | Active | 04-Aug-2020 | ||
| CA-3188036-A1 | Artificial eukaryotic expression system with enhanced performances | Pending | 04-Aug-2020 | ||
| EP-4192849-A1 | Artificial eukaryotic expression system with enhanced performances | Pending | 04-Aug-2020 | ||
| US-20230265479-A1 | Artificial eukaryotic expression system with enhanced performances | Pending | 04-Aug-2020 | C12N9/1247 |
eukarys Signals
eukarys Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Global Health Investment Corporation | Venture Capital | Minority | ||
| BioTools Innovator | Accelerator/Incubator |
eukarys FAQs
-
When was eukarys founded?
eukarys was founded in 2010.
-
Where is eukarys headquartered?
eukarys is headquartered in Evry, France.
-
What is the size of eukarys?
eukarys has 4 total employees.
-
What industry is eukarys in?
eukarys’s primary industry is Discovery Tools (Healthcare).
-
Is eukarys a private or public company?
eukarys is a Private company.
-
What is the current valuation of eukarys?
The current valuation of eukarys is .
-
What is eukarys’s current revenue?
The current revenue for eukarys is .
-
How much funding has eukarys raised over time?
eukarys has raised $717K.
-
Who are eukarys’s investors?
Global Health Investment Corporation and BioTools Innovator have invested in eukarys.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process